1									
2	Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance								
3	to Delamanid in Drug-naïve Patients								
4									
5									
6	Martina L. Reichmuth ^{a*} Rico Hoemke. ^{b,c*} Kathrin Zürcher ^a Peter Sander ^{b,c} Anchalee Avihingsanon. ^d								
7	Jimena Collantes, ^e Chloé Loiseau, ^{f,g} Sonia Borrell, ^{f,g} Miriam Reinhard, ^{f,g} Robert J. Wilkinson, ^{h,l,j} Marcel								
8	Yotebieng ^{k,I} Lukas Fenner ^a Frik C. Böttger ^{b,c} Sebastien Gagneux ^{f,g} Matthias Egger ^{a,m} Peter M								
0	Keller beil on behalf of the International enidemiology Databases to Evaluate AIDS (IeDEA)								
10									
10									
11 12 13 14 15 16 17 18 19 22 23 24 25 26 27 28 20 31 31	 a) Institute of Social and Preventive Medicine, University of Bern, Bern Switzerland b) Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland c) Swiss National Center for Mycobacteria, Zurich, Switzerland d) The HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, Thai Red Cross AIDS Research Centre and Tuberculosis research unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand e) Institute de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru f) Swiss Tropical and Public Health Institute, Basel, Switzerland g) University of Basel, Basel, Switzerland h) Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Republic of South Africa i) Department of Infectious Diseases, Imperial College, London, UK j) The Francis Crick Institute, London, UK k) National TB Lab, Kinshasa, Democratic Republic of the Congo (DRC) l) Albert Einstein College of Medicine, New York, USA m) Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Republic of South Africa n) Institute for Infectious Diseases, University of Bern, Bern, Switzerland 								
32 33 34 35	* Martina L. Reichmuth and Rico Hoemke contributed equally to this work.								
36	Correspondence to:								
37	Peter M. Keller, MD								
38	Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 51, 3001 Bern, Switzerland								
39	peter.keller@ifik.unibe.ch, Phone +41 31 632 35 62								

41 ABSTRACT

42

43 Mutations in the genes of the F₄₂₀ signaling pathway, including *dnn*, *fgd1*, *fbiA*, *fbiB*, *fbiC*, and *fbiD*, of 44 Mycobacterium tuberculosis (Mtb) complex can lead to delamanid resistance. We searched for such mutations among 129 Mtb strains from Asia, South-America, and Africa using whole-genome 45 46 sequencing; 70 (54%) strains had at least one mutation in one of the genes. For ten strains with 47 mutations, we determined the minimum inhibitory concentration (MIC) of delamanid. We found one 48 strain from a delamanid-naïve patient carrying the natural polymorphism Tyr29del (ddn) that was 49 associated with a critical MIC to delamanid. 50 51 52

- 53 Keywords: Mycobacterium tuberculosis, delamanid, resistance, mutations
- 54

55 **Word counts:** Abstract 94 words, main text 1098 words, 36 references, 1 table, 2 supplementary 56 material.

In 2014, the new anti-tuberculosis (TB) drug, delamanid (also known as OPC-67683 or Deltyba™) was 58 59 introduced (1). The World Health Organisation (WHO) recommends the administration of delamanid if 60 a standard effective drug regimen cannot be prescribed due to drug toxicity or resistance (2, 3). Thus, 61 the European Medicines Agency (EMA) conditionally approved delamanid for the treatment of 62 multidrug-resistant (MDR) TB (1, 3, 4). Of note, six years after its market launch, robust and widely accepted breakpoints that define susceptibility and resistance to delamanid still do not exist (5). The 63 few available studies suggest a critical MIC between 0.125 mg/L and 0.2 mg/L, and an Epidemiological 64 65 Cutoff Value (ECOFF) of 0.04 mg/L (6-9). This ECOFF is in line with the WHO (10).

66

67 Delamanid is a drug of the bicyclic nitroimidazole class with potent anti-TB activity (1, 11). It is a pro-68 drug which is activated by the deazaflavin (F_{420}) dependent nitroreductase (ddn) through hydride 69 transfer, forming unstable intermediates, which in turn lead to the formation of reactive nitrogen species 70 (nitric oxide, nitrous acid) (12, 13). Activated delamanid thus has a dual bactericidal mode of action as 71 the primary decomposition product prevents mycolic acid synthesis while the reactive nitrogen species 72 cause respiratory poisoning (12-15). Loss of function mutations in *ddn* or one of the five coenzymes 73 (fqd1, fbiA, fbiB, fbiC, and fbiD) have been proposed as a mechanism of resistance to delamanid (12, 74 13, 16, 17). In vitro, frequencies of delamanid resistance-conferring mutations in the Mycobacterium 75 tuberculosis (*Mtb*) laboratory strain H37Rv and in *M. bovis* range from 2.51×10^{-5} to 6.44×10^{-6} (13). 76 Previous studies have found several resistance-conferring mutations, including Leu107Pro (ddn), 51-77 101del (ddn), Trp88STOP (ddn), Gly81Asp (ddn), Gly81Ser (ddn), Gly53Asp (ddn), c.146_147insC 78 (fad1), Gln88Glu (fad1), Lys250STOP (fbiA), Arg175His (fbiA), and Val318lle (fibC) (6-8, 18-22). 79

80 This multicentre study has been described in detail elsewhere and is part of the International 81 epidemiology Databases to Evaluate AIDS (IeDEA) (23). We identified putative delamanid resistanceconferring mutations in Mtb strains from TB patients living with HIV (PLWH) and HIV negative TB 82 83 patients naïve to delamanid using whole-genome sequencing (WGS) and MIC determination. We 84 collected demographic and clinical characteristics of patients that were recruited between 2013-2016 85 in Peru, Thailand, Côte d'Ivoire, Democratic Republic of the Congo (DRC), Kenya, and South Africa (24, 25). The Cantonal Ethics Committee in Bern, Switzerland, and local institutional review boards 86 approved the study. Written informed consent was obtained at all locations, except in South Africa, 87 88 where consent was not required for archived samples.

89

90 The sequencing pipeline has been described previously (25). In brief, Mtb DNA was extracted and 91 sequenced using Illumina HiSeq 2500 (Illumina, San Diego, CA, USA). For the analysis, we used the 92 well-established pipeline TBprofiler (https://github.com/jodyphelan/TBProfiler (26, 27)). It aligns short 93 reads to the Mtb reference (H37Rv: NC_000962.3) with bowtie2 v2.3.5, BWA v0.7.17 or minimap2 94 v2.16 and then calls variants with SAMtools v1.9 (28-31). To identify putative delamanid resistance-95 conferring mutations, we analysed F₄₂₀ genes (ddn, fgd1, fbiA, fbiB, fbiC, and fbiD) with variant 96 frequencies \geq 75%. A subset of *Mtb* strains with at least one mutation in F₄₂₀ genes were re-cultured in

97 liquid medium and subjected to delamanid MIC determination (<u>Supplementary Figure 1</u>). We assumed
98 that 0.04 mg/L indicates a critical MIC (9).

99

100 We included 129 Mtb isolates among them 52 (40.3%) from Peru, 14 (10.9%) from Thailand, 51 (39.5%) 101 from Côte d'Ivoire, 14 (10.9%) from DRC, and 1 (0.8%) each from Kenya and South Africa. We identified 102 70 (54.3%) isolates with polymorphisms in at least one of the six F_{420} genes as compared to the 103 reference genome (Supplementary Table 1). None of the patients infected with either of these strains 104 had a history of TB and all were naïve to delamanid. We selected strains fulfilling the following criteria: 105 i) mutations in a part of the gene encoding regions of catalytic or structural importance predicted by 106 ARIBA and then the PhyResSE pipeline (32, 33), ii) culture of the strain available iii) bacterial growth amenable to microdilution (25). MIC determination was performed on ten isolates with mutations in the 107 108 F₄₂₀ genes. Four isolates showed a MIC >0.015 mg/L: 0.5 (patient 1), 0.03 (patients 6 and 10), and >8 109 mg/L (patient 9; Table 1; Supplementary Figure 1). The isolate from patient 1 had a polymorphism in 110 fgd1 (Lys270Met), was susceptible to the six tested drugs (isoniazid, rifampicin, ethambutol, 111 pyrazinamide, moxifloxacin, and amikacin). The patient was cured. The isolate from patient 9 had two 112 alterations, a deletion in ddn (Tyr29del) and carried a nucleotide change in fgd1 (T960C). The strain 113 showed an elevated delamanid MIC and was phenotypically susceptible to six other drugs tested. The 114 patient died. Isolates of patient 10 (and 6) had a MIC above 0.015 but below 0.04 mg/L (Table 1). This 115 suggests a low-level resistance to delamanid (22), which could be due to the combination of various mutations: Ala416Val (fbiC), Trp678Gly (fbiC), Arg64Ser (fgd1), and T960C (fgd1). 116

117

118 In summary, in the subset of ten isolates with polymorphisms in the six targeted genes, six had no 119 elevated MIC in the microdultion, while four isolates had (Table 1). In line with previous studies, we 120 found that Lys270Met in fgd1 is a natural polymorphism characteristic of Mtb lineage 4.1.2.1, which may (patient 1 and 6) or may not (patient 7) lead to an increased delamanid MIC (19, 34, 35). All 16 121 122 strains of lineage 4.1.2.1 showed this lineage-specific marker (Supplementary Table 1). Furthermore, 123 T960C (fgd1) is a synonymous substitution and was found in three other patient isolates which 124 expectedly did not have a critical MIC. The increase in the delamanid MIC in the isolate of patient 9 was 125 due to the deletion in ddn (7). Our results thus suggest that Tyr29del is a natural polymorphism leading 126 to an increased delamanid MIC. Our study was too small to estimate the prevalence of strains that are 127 naturally resistant to delamanid. Lee et al. 2020, screened 14,876 Mtb strains and found two strains 128 with Tyr29del, for a prevalence of 0.013% (36). However, in their study, only the ddn gene was screened 129 and the prevalence of natural resistance could, therefore, be higher.

130

131 In conclusion, we confirm that mutations in F_{420} genes can confer an elevated delamanid MIC (13, 19).

132 Whether our findings also apply to the related drug pretomanid should be investigated in future studies.

133 The occurrence of clinical *Mtb* isolates with naturally elevated MICs to delamanid from previously

- untreated patients calls for careful drug susceptibility testing (DST) prior to delamanid treatment (5, 36).
- 135 However, access to DST is limited in high burden countries. This dilemma highlights the conflict

- between making new drugs available in high-burden countries and avoiding spread of drug-resistantstrains.
- 138
- Data availability. WGS data from patients *Mtb* strains shown in Table 1 have been submitted to the
 NCBI (PRJNA300846; Supplementary Table 1).
- 141

142 ACKNOWLEDGMENTS

We thank all sites that participated, patients whose data were used in this study and Marie Ballif for
contributing to the data collection and for critically reading the manuscript. Calculations were performed
on UBELIX (http://www.id.unibe.ch/hpc), the HPC cluster at the University of Bern.

146

147 ROLE OF FUNDING SOURCE

148 This research was supported by the Swiss National Foundation (project grant numbers 153442, 149 310030_166687, 310030_188888, IZRJZ3_164171, IZLSZ3_170834 and CRSII5_177163). The International Epidemiology Databases to Evaluate AIDS (IeDEA) is supported by the U.S. National 150 151 Institutes of Health's, National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National 152 153 Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and 154 155 Digestive and Kidney Diseases, the Fogarty International Center, and the National Library of Medicine: 156 Asia- Pacific, U01AI069907; CCASAnet, U01AI069923; Central Africa, U01AI096299; East Africa, U01AI069911; NA-ACCORD, U01AI069918; Southern Africa, U01AI069924; West Africa, 157 U01AI069919. RJW receives support from the Francis Crick Institute, which is funded by UKRI, CRUK, 158 159 and Wellcome (FC0010218, 104803, 203135). This work is solely the responsibility of the authors and 160 does not necessarily represent the official views of any of the institutions mentioned above. This manuscript is not peer-reviewed. 161

162

163 CONFLICT OF INTEREST

- 164 Authors have nothing to disclose.
- 165

medRxiv preprint doi: https://doi.org/10.1101/2020.08.07.20167130; this version posted August 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

166 REFERENCE

- 1. Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J. 2018. 167 168 Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). 169 Tuberculosis (Edinb) 111:20-30.
- 170 2. Esmail A, Sabur NF, Okpechi I, Dheda K. 2018. Management of drug-resistant tuberculosis in 171 special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-172 specific dysfunction, and in the critically ill. J Thorac Dis 10:3102-3118.
- 173 3. WHO. Consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health 174 Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
- EMA. 2018. Deltyba (delamanid): An overview of Deltyba and why it is authorised in the EU. 175 4. 176 Agency EM, London, United Kingdom.
- 177 5. Koser CU, Maurer FP, Kranzer K. 2019. 'Those who cannot remember the past are condemned 178 to repeat it': Drug-susceptibility testing for bedaquiline and delamanid. Int J Infect Dis 80S:S32-179 S35.
- 180 6. Stinson K, Kurepina N, Venter A, Fujiwara M, Kawasaki M, Timm J, Shashkina E, Kreiswirth BN, Liu Y, Matsumoto M, Geiter L. 2016. MIC of Delamanid (OPC-67683) against 181 182 Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration. Antimicrob 183 Agents Chemother 60:3316-22.
- 184 7. Schena E, Nedialkova L, Borroni E, Battaglia S, Cabibbe AM, Niemann S, Utpatel C, Merker 185 M, Trovato A, Hofmann-Thiel S, Hoffmann H, Cirillo DM. 2016. Delamanid susceptibility testing 186 of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 187 system. J Antimicrob Chemother 71:1532-9.
- 188 8. Hoffmann H, Kohl TA, Hofmann-Thiel S, Merker M, Beckert P, Jaton K, Nedialkova L, 189 Sahalchyk E, Rothe T, Keller PM, Niemann S. 2016. Delamanid and Bedaquiline Resistance 190 in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant 191 Tuberculosis in a Tibetan Refugee. Am J Respir Crit Care Med 193:337-40.
- 192 9. Keller PM, Homke R, Ritter C, Valsesia G, Bloemberg GV, Bottger EC. 2015. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in 193 194 Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST. Antimicrob 195 Agents Chemother 59:4352-5.
- 196 10. WHO. Technical Report on critical concentrations for drug susceptibility testing of medicines 197 used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2018 198 (WHO/CDS/TB/2018.5). Licence: CC BY-NC-SA 3.0 IGO.
- 199 11. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa 200 Y, Komatsu M. 2006. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising 201 action against tuberculosis in vitro and in mice. PLoS Med 3:e466.
- Purwantini E, Mukhopadhyay B. 2009. Conversion of NO2 to NO by reduced coenzyme F420 202 12. 203 protects mycobacteria from nitrosative damage. Proc Natl Acad Sci U S A 106:6333-8.
- Fujiwara M, Kawasaki M, Hariguchi N, Liu Y, Matsumoto M. 2018. Mechanisms of resistance 204 13. 205 to delamanid, a drug for Mycobacterium tuberculosis. Tuberculosis (Edinb) 108:186-194.
- 206 Greening C, Ahmed FH, Mohamed AE, Lee BM, Pandey G, Warden AC, Scott C, Oakeshott 14. JG, Taylor MC, Jackson CJ. 2016. Physiology, Biochemistry, and Applications of F420- and 207 208 Fo-Dependent Redox Reactions. Microbiol Mol Biol Rev 80:451-93.

medRxiv preprint doi: https://doi.org/10.1101/2020.08.07.20167130; this version posted August 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 209 15. Van den Bossche A, Varet H, Sury A, Sismeiro O, Legendre R, Coppee JY, Mathys V, 210 Ceyssens PJ. 2019. Transcriptional profiling of a laboratory and clinical Mycobacterium 211 tuberculosis strain suggests respiratory poisoning upon exposure to delamanid. Tuberculosis 212 (Edinb) 117:18-23.
- 213 16. Rifat D, Li S-Y, loerger T, Lanoix J-P, Lee J, Bashiri G, Sacchettini J, Nuermberger E. 2018. 214 Mutations in Rv2983 as a novel determinant of resistance to nitroimidazole drugs in 215 Mycobacterium tuberculosis. bioRxiv preprint doi:10.1101/457754.
- 216 17. Bashiri G. Antonev J. Jirgis ENM, Shah MV, Nev B. Copp J. Stutelev SM, Sreebhavan S. 217 Palmer B, Middleditch M, Tokuriki N, Greening C, Scott C, Baker EN, Jackson CJ. 2019. A revised biosynthetic pathway for the cofactor F420 in prokaryotes. Nat Commun 10:1558. 218
- 219 18. Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, 220 Homke R, Ritter C, Feldmann J, Schulthess B, Gagneux S, Bottger EC. 2015. Acquired 221 Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. N Engl J Med 373:1986-222 8.
- Feuerriegel S, Koser CU, Bau D, Rusch-Gerdes S, Summers DK, Archer JA, Marti-Renom MA, 223 19. 224 Niemann S. 2011. Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on 225 in vitro susceptibility to PA-824. Antimicrob Agents Chemother 55:5718-22.
- 226 20. Yang JS, Kim KJ, Choi H, Lee SH. 2018. Delamanid, Bedaquiline, and Linezolid Minimum 227 Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-228 resistant and Extensively Drug-resistant Tuberculosis in Korea. Ann Lab Med 38:563-568.
- 229 21. Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L, Li Y, Zhao L, Fu Y, Huang H. 2017. In Vitro 230 Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and 231 Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China. Antimicrob 232 Agents Chemother 61.
- 233 22. Polsfuss S, Hofmann-Thiel S, Merker M, Krieger D, Niemann S, Russmann H, Schonfeld N, 234 Hoffmann H, Kranzer K. 2019. Emergence of Low-level Delamanid and Bedaquiline Resistance 235 During Extremely Drug-resistant Tuberculosis Treatment. Clin Infect Dis 69:1229-1231.
- 23. Antiretroviral Therapy in Low-Income Countries Collaboration of the International 236 epidemiological Databases to Evaluate A, Collaboration ARTC, Brinkhof MW, Egger M, Boulle 237 A, May M, Hosseinipour M, Sprinz E, Braitstein P, Dabis F, Reiss P, Bangsberg DR, 238 239 Rickenbach M, Miro JM, Myer L, Mocroft A, Nash D, Keiser O, Pascoe M, van der Borght S, 240 Schechter M. 2007. Tuberculosis after initiation of antiretroviral therapy in low-income and highincome countries. Clin Infect Dis 45:1518-21. 241
- 242 24. Zürcher K, Ballif M, Fenner L, Borrell S, Keller PM, Gnokoro J, Marcy O, Yotebieng M, Diero L, 243 Carter EJ, Rockwood N, Wilkinson RJ, Cox H, Ezati N, Abimiku AlG, Collantes J, Avihingsanon 244 A, Kawkitinarong K, Reinhard M, Hömke R, Huebner R, Gagneux S, Böttger EC, Egger M, 245 Zürcher K, Egger M, Fenner L, Ballif M, Chammartin F, Gagneux S, Borrell S, Reinhard M, Boettger EC, Keller P, Hömke R, Abimiku AI, Ezati N, Yotebieng M, Wenzi L, Tabala M, Cox H, 246 247 Rockwood N, Warren R, Streicher E, Wilkinson RJ, Carter EJ, Diero L, Collantes J, Zamudio 248 C, Huebner R, et al. 2019. Drug susceptibility testing and mortality in patients treated for 249 tuberculosis in high-burden countries: a multicentre cohort study. The Lancet Infectious 250 Diseases 19:298-307.
- 251 25. Gygli SM, Keller PM, Ballif M, Blochliger N, Homke R, Reinhard M, Loiseau C, Ritter C, Sander 252 P, Borrell S, Collantes Loo J, Avihingsanon A, Gnokoro J, Yotebieng M, Egger M, Gagneux S, 253 Bottger EC. 2019. Whole-Genome Sequencing for Drug Resistance Profile Prediction in 254 Mycobacterium tuberculosis. Antimicrob Agents Chemother 63.
- 255 26. Phelan JE, O'Sullivan DM, Machado D, Ramos J, Oppong YEA, Campino S, O'Grady J, 256 McNerney R, Hibberd ML, Viveiros M, Huggett JF, Clark TG. 2019. Integrating informatics tools

- and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs.
 Genome Med 11:41.
- Coll F, Phelan J, Hill-Cawthorne GA, Nair MB, Mallard K, Ali S, Abdallah AM, Alghamdi S, 259 27. 260 Alsomali M, Ahmed AO, Portelli S, Oppong Y, Alves A, Bessa TB, Campino S, Caws M, 261 Chatterjee A, Crampin AC, Dheda K, Furnham N, Glynn JR, Grandjean L, Minh Ha D, Hasan R, Hasan Z, Hibberd ML, Joloba M, Jones-Lopez EC, Matsumoto T, Miranda A, Moore DJ, 262 Mocillo N, Panaiotov S, Parkhill J, Penha C, Perdigao J, Portugal I, Rchiad Z, Robledo J, Sheen 263 P, Shesha NT, Sirgel FA, Sola C, Oliveira Sousa E, Streicher EM, Helden PV, Viveiros M, 264 Warren RM, McNerney R, Pain A, et al. 2018. Genome-wide analysis of multi- and extensively 265 266 drug-resistant Mycobacterium tuberculosis. Nat Genet 50:307-316.
- 267 28. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform.
 268 Bioinformatics 25:1754-60.
- 269 29. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R,
 270 Genome Project Data Processing S. 2009. The Sequence Alignment/Map format and
 271 SAMtools. Bioinformatics 25:2078-9.
- 30. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler
 D, Gabriel S, Daly M, DePristo MA. 2010. The Genome Analysis Toolkit: a MapReduce
 framework for analyzing next-generation DNA sequencing data. Genome Res 20:1297-303.
- Li H. 2011. A statistical framework for SNP calling, mutation discovery, association mapping
 and population genetical parameter estimation from sequencing data. Bioinformatics 27:2987 93.
- 32. Hunt M, Mather AE, Sanchez-Buso L, Page AJ, Parkhill J, Keane JA, Harris SR. 2017. ARIBA:
 rapid antimicrobial resistance genotyping directly from sequencing reads. Microb Genom
 3:e000131.
- 33. Feuerriegel S, Schleusener V, Beckert P, Kohl TA, Miotto P, Cirillo DM, Cabibbe AM, Niemann
 S, Fellenberg K. 2015. PhyResSE: a Web Tool Delineating Mycobacterium tuberculosis
 Antibiotic Resistance and Lineage from Whole-Genome Sequencing Data. J Clin Microbiol
 53:1908-14.
- Feuerriegel S, Koser CU, Niemann S. 2014. Phylogenetic polymorphisms in antibiotic
 resistance genes of the Mycobacterium tuberculosis complex. J Antimicrob Chemother
 69:1205-10.
- 35. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, Angeby K, Jureen P, Moradigaravand D, Parkhill J, Peacock SJ, Schon T, Maurer FP, Walker T, Koser C, Niemann S. 2020. Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med 12:27.
- 36. Lee BM, Harold LK, Almeida DV, Afriat-Jurnou L, Aung HL, Forde BM, Hards K, Pidot SJ,
 Ahmed FH, Mohamed AE, Taylor MC, West NP, Stinear TP, Greening C, Beatson SA,
 Nuermberger EL, Cook GM, Jackson CJ. 2020. Predicting nitroimidazole antibiotic resistance
 mutations in Mycobacterium tuberculosis with protein engineering. PLoS Pathog 16:e1008287.
- 296

No.	Lineage	Country	HIV	Age at	Gender	Mutations in the F ₄₂₀ genes	Treatment	Treatment	MIC mg/L in
			status	ТВ				outcome	the micro-
				diagnosis					dilution
0	H37Rv	-	-	-	-	Control (wt)	-	-	≤0.015
	ATCC								
	27294								
1	L4.1.2.1	Côte d'Ivoire	Negative	29	Female	fgd1 Lys270Met	2HRZE, 4RH	Cured	0.5
2	L4.6.2.2	Côte d'Ivoire	Negative	51	Male	ddn C168T	2HRZE, 4RH	Died	≤0.015
3	L2.2.1	Kenya	Positive	40	Male	fgd1 T960C	2HRZE, 4RH	Died	≤0.015
4	L2.2.1	Peru	Positive	28	Male	fgd1 T960C	2HRZE, 4RH	Unknown	≤0.015
5	L4.3.2	Peru	Negative	21	Male	fbiC C1161T	2HRZE, 4RH	Cured	≤0.015
6	L4.1.2.1	Peru	Positive	45	Male	fgd1 Lys270Met	2HRZE, 4RH	Unknown	0.03
7	L4.1.2.1	Peru	Positive	36	Male	fbiC G-11A	2HRZE, 4RH	Unknown	≤0.015
						fgd1 Lys270Met			
8	L4.1.2	South Africa	Negative	57	Female	<i>fbiA</i> Ile208Val	2HRZE, 4RH	Cured	≤0.015
9	L2.2.1	Thailand	Unknown	76	Male	fgd1 T960C	2HRZE, 4RH	Died	>8
						<i>ddn</i> 85-87del (Tyr29del)			
10	L1.1.1	Thailand	Negative	42	Male	fbiC Ala416Val, Trp678Gly	2HRZE, 4RH	Unknown	0.03
						fgd1 Arg64Ser, T960C			

298 TABLE 1. Observed polymorphisms in F₄₂₀ genes and minimal inhibitory concentration values for delamanid.

299 Abbreviations: MIC, minimal inhibitory concentration; No, number; L, lineage; wt, wild-type; H, isoniazid; R, rifampicin; Z, pyrazinamide; E, ethambutol.